TEXTILES.ORG
Hohenstein Medical, a division of Hohenstein Laboratories, has hired Katie Brinkman as its biocompatibility program manager to lead and support the company’s growing biocompatibility service offerings. In this role, Brinkman will lead the development and strategic positioning of Hohenstein Medical’s device biocompatibility program, with a focus on chemical characterization, ISO 18562 gas pathway testing and ethical, non-animal assays.
“We’re thrilled to welcome Katie to the Hohenstein Medical team as we continue to serve our customers using the highest international standards for regulatory studies and lab competence,” says Timo Hammer, CEO at Hohenstein Medical. “As we grow our biocompatibility program, we remain focused on bringing in a team that exemplifies excellence, starting with care, and Katie does just that through her dedication and expertise in medical device testing and consulting.”
Before joining Hohenstein Medical, Brinkman served in biocompatibility roles at Cook Research Incorporated, NAMSA, Abbott and Ethicon Endo-Surgery, Inc. (a Johnson & Johnson company), where she authored numerous biocompatibility and toxicological risk assessment reports supporting global regulatory submissions. Her work spans the entire medical device lifecycle—from new product development and design changes to the European Union Medical Device Regulation remediation and post-market evaluations.
“Biocompatibility is nuanced and intricate, and I am excited to join Hohenstein Medical to bring my technical experience and passion for testing excellence together with Hohenstein’s focus on individualized support in caring for customers,” says Brinkman. “I look forward to creating a program that supports customers with a hands-on approach to make the biocompatibility process as smooth as possible.”